Aptahem AB (publ) (APTA.ST)
SEK 1.6
(-3.03%)
SEK 1.6
(-3.03%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -10 Million SEK | -10.44% |
| 2022 | -8.79 Million SEK | 68.17% |
| 2021 | -28.41 Million SEK | -17.69% |
| 2020 | -24.2 Million SEK | -38.9% |
| 2019 | -17.42 Million SEK | 15.1% |
| 2018 | -20.52 Million SEK | -102.27% |
| 2017 | -10.14 Million SEK | -4.99% |
| 2016 | -9.66 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -2.6 Million SEK | -4.24% |
| 2024 Q1 | -2.5 Million SEK | 22.7% |
| 2023 FY | - SEK | -10.44% |
| 2023 Q2 | -2.74 Million SEK | -13.76% |
| 2023 Q3 | -1.55 Million SEK | 43.28% |
| 2023 Q4 | -3.29 Million SEK | -111.62% |
| 2023 Q1 | -2.41 Million SEK | 20.49% |
| 2022 Q2 | -2.11 Million SEK | -11.07% |
| 2022 FY | - SEK | 68.17% |
| 2022 Q4 | -3.03 Million SEK | -51.15% |
| 2022 Q3 | -2 Million SEK | 5.15% |
| 2022 Q1 | -1.9 Million SEK | 69.65% |
| 2021 Q3 | -5.17 Million SEK | -9.4% |
| 2021 FY | - SEK | -17.69% |
| 2021 Q2 | -4.73 Million SEK | 0.0% |
| 2021 Q4 | -6.28 Million SEK | -21.28% |
| 2020 FY | - SEK | -38.9% |
| 2019 FY | - SEK | 15.1% |
| 2018 FY | - SEK | -102.27% |
| 2017 FY | - SEK | -4.99% |
| 2016 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 97.279% |
| AcouSort AB (publ) | -16.7 Million SEK | 40.075% |
| Active Biotech AB (publ) | -43.88 Million SEK | 77.193% |
| Alzinova AB (publ) | 41.99 Thousand SEK | 23932.06% |
| Amniotics AB (publ) | -27.14 Million SEK | 63.124% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | 29.597% |
| BioArctic AB (publ) | 275.38 Million SEK | 103.635% |
| Camurus AB (publ) | 562.54 Million SEK | 101.779% |
| Cantargia AB (publ) | -284.31 Million SEK | 96.48% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | 48.878% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | 41.413% |
| Genovis AB (publ.) | 64.57 Million SEK | 115.501% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | 91.289% |
| Mendus AB (publ) | -97.84 Million SEK | 89.77% |
| Kancera AB (publ) | -61.88 Million SEK | 83.827% |
| Karolinska Development AB (publ) | -26.78 Million SEK | 62.628% |
| LIDDS AB (publ) | -39.67 Million SEK | 74.769% |
| Lipum AB (publ) | -37.11 Million SEK | 73.035% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | 17.306% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 131.872% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | 500561.35% |
| NextCell Pharma AB | -40.98 Million SEK | 75.578% |
| OncoZenge AB (publ) | 7.26 Million SEK | 237.754% |
| Saniona AB (publ) | -69.69 Million SEK | 85.639% |
| Simris Alg AB (publ) | -22.36 Million SEK | 55.242% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 96.847% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | 96.451% |
| Xintela AB (publ) | -53.47 Million SEK | 81.281% |
| Ziccum AB (publ) | -20.34 Million SEK | 50.795% |
| Isofol Medical AB (publ) | -37.02 Million SEK | 72.966% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | 94.106% |
| CombiGene AB (publ) | -35.33 Million SEK | 71.674% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | 92.894% |
| Intervacc AB (publ) | -68.98 Million SEK | 85.49% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | 95.788% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | -381.213% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | 25.477% |
| Corline Biomedical AB | -1.69 Million SEK | -491.912% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | 94.225% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | 81.737% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 186.667% |
| Fluicell AB (publ) | -25.91 Million SEK | 61.375% |
| Biovica International AB (publ) | -119.5 Million SEK | 91.624% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 76.295% |
| Abliva AB (publ) | -93.6 Million SEK | 89.307% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 96.863% |
| 2cureX AB (publ) | -35.13 Million SEK | 71.513% |
| I-Tech AB | 30.34 Million SEK | 132.985% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 98.599% |
| Cyxone AB (publ) | -20.41 Million SEK | 50.969% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | 90.23% |
| Biosergen AB | 228 Thousand SEK | 4490.012% |
| Nanologica AB (publ) | -62.11 Million SEK | 83.887% |
| SynAct Pharma AB | -222.7 Million SEK | 95.506% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | 77.18% |
| BioInvent International AB (publ) | -312.7 Million SEK | 96.799% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 3334.908% |
| Oncopeptides AB (publ) | -231.62 Million SEK | 95.679% |
| Pila Pharma AB (publ) | -8.81 Million SEK | -13.58% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | 90.78% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | 12.728% |